---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019976"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:56:01.680074+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "medium"
source: SEC EDGAR
---

# Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis

## Summary
- Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.
- Consideration includes one-time upfront payment, net-sales milestone payments, and a share of U.S. net sales (amounts not disclosed).
- Transition of commercial rights from Biogen to Samsung expected by end of 2025; Harrow will then assume full commercialization.
- U.S. retinal disease treatment market valued at ~$9B; products target Wet AMD, Macular Edema, DME, and Diabetic Retinopathy.
- CEO Mark Baum calls the acquisition transformational, reinforcing Harrow's commitment to affordable alternatives in eyecare.

## SEC filing metadata
- accession: 0001641172-25-019976
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/0001641172-25-019976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019976
- JSON: https://secwatch.observer/filing/0001641172-25-019976.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.